Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

Haematologica
Phillip L R NicolsonSteve P Watson

Abstract

Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and phosphorylation of downstream substrates including phospholipase C-γ2. In the present study, we demonstrate that concentrations of ibrutinib and acalabrutinib that block Bruton tyrosine kinase activity, as shown by loss of phosphorylation at tyrosine 223 and phospholipase C-γ2, delay but do not block aggregation in response to a maximally-effective concentration of collagen-related peptide or collagen. In contrast, 10- to 20-fold higher concentrations of ibrutinib or acalabrutinib block platelet aggregation in response to glycoprotein VI agonists. Ex vivo studies on patients treated with ibrutinib, but not acalabrutinib, showed a reduction of platelet aggregation in response to collagen-related peptide indicating that the clinical dose of ibrutinib but not acalabrutinib is supramaximal for Bruton tyrosine kinase blockade. Unexpectedly, low concentrations of ibrutinib inhibited aggregation in response to collagen-related peptide in patients deficient in Bruton tyrosine kinase. The increased...Continue Reading

Citations

Apr 28, 2019·Current Hematologic Malignancy Reports·David A Bond, Jennifer A Woyach
Nov 5, 2019·Journal of Thrombosis and Haemostasis : JTH·Joanne L DunsterAlice Y Pollitt
Mar 5, 2020·Platelets·Elizabeth J HainingSteve P Watson
Apr 3, 2020·American Society of Clinical Oncology Educational Book·Farrukh T AwanJennifer A Woyach
Jun 20, 2020·Platelets·Phillip Lr NicolsonSteve P Watson
Jan 3, 2019·The Journal of Clinical Investigation·Julie RayesBernhard Nieswandt
Apr 1, 2020·Chemical Society Reviews·Ayah AbdeldayemPatrick T Gunning
Sep 8, 2020·Platelets·Wolfgang SiessReinhard Lorenz
Nov 22, 2019·Frontiers in Immunology·Nonantzin Beristain-CovarrubiasAdam F Cunningham
Sep 15, 2020·Journal of Thrombosis and Haemostasis : JTH·Jennifer SeriesBernard Payrastre
Jan 3, 2021·Haematologica·Bernard Payrastre, Agnès Ribes
Jan 18, 2020·Haematologica·Phillip L R NicolsonCraig E Hughes
Dec 15, 2020·Platelets·Maan H HarbiMark R Thomas
Mar 11, 2021·American Journal of Physiology. Cell Physiology·Tony J ZhengJoseph E Aslan
Apr 4, 2021·Cancers·Philipp von Hundelshausen, Wolfgang Siess
Mar 30, 2021·Frontiers in Cell and Developmental Biology·H Yesid EstupiñánC I Edvard Smith
Jun 28, 2021·Hematology/oncology Clinics of North America·Masa Lasica, Constantine S Tam
Dec 23, 2021·Journal of Thrombosis and Haemostasis : JTH·Zhaogong ZhiAsif J Iqbal

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
transfections
immunoprecipitation
transfection

Software Mentioned

Optimul
ImageJ
GraphPad Prism

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.